On May 6, 2023, the 7th Future Healthcare VB100 Conference, jointly organized by VB100, Vcbeat.top, and VCBeat Research, was held in Zhangjiang Hi-Tech Park of Shanghai. Concurrently, the “2023 Future Healthcare VB100 List” was unveiled. This is the first domestic list specifically focusing on innovative medical enterprises that are not publicly listed. It is regarded as the most anticipated annual selection within the life and health domain. Capturing significant attention from industry professionals and the capital market. It is commonly referred to as the industry’s “investment compass.” 

Bolstered by its remarkable growth momentum, pioneering capabilities, and exceptional performance in CGT customer service and successful application cases, EurekaBio has secured its prominent position in the “2023 Future Healthcare VB100 – China’s TOP100 Innovative Medical Companies and Supply Chain Service Providers” ranking. Furthermore, Dr. Xue Bofu, founder and CSO of EurekaBio was bestowed the esteemed  “2023 Future Healthcare VB100 Weilan Awards – Most Innovative Entrepreneurs”. 
The “2023 Future Healthcare VB100 – China’s TOP100 Innovative Medical Companies and Supply Chain Service Providers” aims to recognize the enterprises that demonstrate excellence in delivering commercial services and supply chain solutions to diverse users, including hospitals, businesses, and other medical institutions. These enterprises operate across various fields related to life science tools and services, which encompass a wide range of activities. This includes but is not limited to, providing pharmaceutical and device CRO/CMO/CDMO services as well as sourcing upstream raw materials, consumables, and equipment within the pharmaceutical and device industries.
Amid fierce competition among over 1,000 participating companies, EurekaBio has emerged as a winner, securing two prestigious awards. This significant achievement not only highlights the company’s exceptional technical expertise, outstanding product performance, and unwavering commitment to delivering top-notch customer service in the field of CGT but also signifies an industry-wide recognition of EurekaBio’s  accomplishments in research and development, its business model and investment value across multiple dimensions.
Founded in 2014, EurekaBio has maintained a deep commitment to the field of CGT for nearly a decade. Through commendable achievements in fully closed and automated equipment and CGT technology services, the company has established a unique and diversified business layout.  One of EurekaBio’s notable innovations is the EuLV®system, a production platform for lentiviral vectors based on stable cell producer lines. This globally leading technology has successfully addressed the challenges associated with scaling up the production of lentiviral vectors. Additionally, their independently developed CellSep®series cell processing systems have played a crucial role in supporting nearly 30 domestic CGT companies in filing their IND applications. 
Moving forward, EurekaBio is determined to continue its commitment to ceaseless innovation, increasing technological investment, extensive product diversification, and meeting the expanding demands of customers. In doing so, the company aims to drive the commercialization of CGT in China to new heights.